DCC-2036 (Rebastinib)

• Post Date:

  Apr 03,2015

• Expiry Date:

  Apr 02,2016

• Detailed Description:

  Cas No. :1020172-07-9 Quantity: 50g
  Specs:98% purity
  Payment Method: T/T, Western Union
  
  
  DCC-2036 is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor DCC-2036 binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Multitargeted tyrosine kinase inhibitor DCC-2036 may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response.
  

• CAS Registry Number:

  1020172-07-9

• Company:

  Shanghai Sun-shineChemical Technology Co.,Ltd.     [ China ]        

• Contact:

  Rosie

• Tel:

  +86-027-59253327

• Fax:

  0086-27-5925 3326

• Email:

  sales02@sun-shinechem.com